Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension
Not yet recruiting · Early phase 1 · NCT07116681
Conditions: Pulmonary Hypertension
At a glance
- Research payments reported, 2025
- $72,543
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 8
About the trial
- Sponsor
- University of California, San Diego (with United Therapeutics)
- Tested
- Inhaled treprostinil (drug)
- Dates
- Started 2025-10-01; completion 2027-07-01
- Results posted
- Not yet
This study aims to investigate therapies for exercise induced pulmonary hypertension (EiPH). This is a condition that effects the blood vessels in the lungs and causes shortness of breath with activity. Currently, there are very limited treatment options for this condition. Inhaled treprostinil, also known as Tyvaso, is a medication used to treat other forms of lung disease and is safe and well tolerated. This study will measure the ability of Tyvaso to improve symptoms related to EiPH and improve performance on exercise testing.
From ClinicalTrials.gov, last updated 2025-08-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
United Therapeutics Corporation reported $72,543 in research payments for this study in 2025 (1 payments).
Products named: Tyvaso
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Regents of the University of California $72,543
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.